Delivery Order SPE2DB22D9244-SPE2DB25FZS52
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $12,115.65 by the Defense Logistics Agency on August 12, 2025, for the supply of Jakafi 10 mg tablets (60-count). This delivery order was issued without a set-aside designation and carries an ultimate completion date of August 13, 2025. The award represents a task order under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,115.65 by the Defense Logistics Agency on July 23, 2025, for the supply of Jakafi 10 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Jakafi 15 mg tablets (60-count units) with a ceiling value of $11,999.80. The contract is classified as a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and was awarded on August 1, 2025. This award utilizes no set-aside designation, allowing DMS Pharmaceutical Group to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,146.79 by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Jakafi 5 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis leveraging its established...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $24,293.60 on July 28, 2025, for the supply of Jakafi 5 mg tablets (60-count units). The contract, which carries no set-aside designation, is issued under DMS's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at approximately $500 million through November 2026. This delivery order will be...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $24,231.30 by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Jakafi 10 mg tablets (60-count). This firm fixed-price delivery order is expected to be completed by July 31, 2025, and represents a continuation of the company's significant role as a federal pharmaceutical supplier. The award carries no set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 31, 2025, by the Defense Logistics Agency for the supply of Jakafi 10 mg tablets (60-count unit). This firm fixed-price delivery order, valued at $24,231.30, represents a single shipment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program. The contract includes no set-aside designation, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $65,476.32 for Jakafi 10 mg tablets (60-count units) by the Defense Logistics Agency on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's substantial pharmaceutical supply relationship with the Department of Defense....
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,115.65 by the Defense Logistics Agency on July 21, 2025, for the supply of Jakafi 10 mg tablets (60-count packages). The contract utilizes a firm fixed-price structure with no set-aside designation and carries an ultimate completion date of July 22, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $24,293.60 on August 11, 2025, for the supply of Jakafi 5 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, was issued without a set-aside designation by the Defense Logistics Agency's Medical Supply Chain under the SPE2DB Indefinite Delivery Contract program. The...
- SPE2DB22D9244Indefinite Delivery Contract
- SPE2DB22D9244-SPE2DB25FZS52Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $24,231.30 by the Defense Logistics Agency on August 11, 2025, for the supply of Jakafi 10 mg tablets (60-count units). The contract carries no set-aside designation and is scheduled for completion by August 12, 2025, with performance to occur at the contractor's Park Ridge, Illinois facility. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion vehicle valid through November 2026 that authorizes the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense medical facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, maintaining a robust portfolio of delivery orders covering branded and generic prescription drugs, biologics, and specialized medical consumables. The company's consistent procurement success with the DLA reflects its capability to deliver specialized pharmaceutical products, including oncology treatments and other high-value medications, directly to military healthcare systems. This specific award for Jakafi—a medication indicated for myelofibrosis treatment—exemplifies the contractor's role in ensuring Department of Defense medical facilities have access to specialized prescription pharmaceuticals necessary for patient care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.2k | 8/11/25 |